IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

Recipharm invests in Synthonics; the companies announce a joint development agreement

6:34 AM MDT | April 14, 2015 | Michael Ravenscroft

Recipharm (Jordbro, Sweden), a contract development and manufacturing organization, says it has today made a strategic investment in Synthonics (Blacksburg, VA), a specialty pharmaceutical company focused on the discovery, development, and licensing of metal-coordinated compounds. Recipharm has purchased $2.0 million of preferred stock in Synthonics. A further $2.0 million of preferred stock will be purchased with Synthonics’ achievement of certain milestones, which could be expected during 2016, according to Recipharm. The two companies have also entered...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa